BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28456566)

  • 1. Assessment of acute and chronic toxicity of doxorubicin in human induced pluripotent stem cell-derived cardiomyocytes.
    Louisse J; Wüst RCI; Pistollato F; Palosaari T; Barilari M; Macko P; Bremer S; Prieto P
    Toxicol In Vitro; 2017 Aug; 42():182-190. PubMed ID: 28456566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
    Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
    Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Ellis JK; Wagh V; Nemade H; Hescheler J; Keun HC; Sachinidis A
    Amino Acids; 2017 Dec; 49(12):1955-1963. PubMed ID: 28421296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin Cytotoxicity in Differentiated H9c2 Cardiomyocytes: Evidence for Acute Mitochondrial Superoxide Generation.
    Helal M; Alcorn J; Bandy B
    Cardiovasc Toxicol; 2021 Feb; 21(2):152-161. PubMed ID: 32910361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
    Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
    Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.
    Holmgren G; Synnergren J; Bogestål Y; Améen C; Åkesson K; Holmgren S; Lindahl A; Sartipy P
    Toxicology; 2015 Feb; 328():102-11. PubMed ID: 25529476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.
    Yang N; Ma H; Jiang Z; Niu L; Zhang X; Liu Y; Wang Y; Cheng S; Deng Y; Qi H; Wang Z
    Biochem Biophys Res Commun; 2019 Sep; 517(1):111-117. PubMed ID: 31303273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The assessment of electrophysiological activity in human-induced pluripotent stem cell-derived cardiomyocytes exposed to dimethyl sulfoxide and ethanol by manual patch clamp and multi-electrode array system.
    Hyun SW; Kim BR; Hyun SA; Seo JW
    J Pharmacol Toxicol Methods; 2017 Sep; 87():93-98. PubMed ID: 28377112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
    Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
    Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin activates SIRT1 to protect human cardiomyocytes against doxorubicin-induced mitochondrial dysfunction and toxicity.
    Cui L; Guo J; Zhang Q; Yin J; Li J; Zhou W; Zhang T; Yuan H; Zhao J; Zhang L; Carmichael PL; Peng S
    Toxicol Lett; 2017 Jun; 275():28-38. PubMed ID: 28456571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of doxorubicin-induced cytotoxicity and mitochondrial damage by betanin in rat isolated cardiomyocytes and mitochondria.
    Hafez AA; Jamali Z; Samiei S; Khezri S; Salimi A
    Hum Exp Toxicol; 2021 Dec; 40(12):2123-2134. PubMed ID: 34105389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of gentamicin and penicillin/streptomycin on the electrophysiology of human induced pluripotent stem cell-derived cardiomyocytes in manual patch clamp and multi-electrode array system.
    Hyun SW; Kim BR; Lin D; Hyun SA; Yoon SS; Seo JW
    J Pharmacol Toxicol Methods; 2018; 91():1-6. PubMed ID: 29288713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.